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This editorial refers to ‘Peripheral arterial disease and crit-
ical limb ischaemia: still poor outcomes and lackof guideline
adherence’†, by H. Reinecke et al., on page 932.
Peripheral artery diseaseof the lowerextremities (PAD) has become
increasingly recognized as a major contributor to the cardiovascular
public health burden. It identifies a cohort of patients at increased risk
of major cardiovascular ischaemic events. Moreover, its prevalence
steadily increases as the population ages, becomes more obese,
and as diabetes becomes more common. The German epidemio-
logical trial on ankle brachial index (GetABI) and the Registry REduc-
tion in Atherothrombosis for Continued Health Registry (REACH)
have highlighted that even asymptomatic subjects with PAD have a
prognosis almost as poor as that of patients with symptomatic
disease, and demonstrated a greater degree of undertreatment of
atherosclerosis risk factors relative to those with coronary artery
disease or cerebrovascular disease.1,2 Follow-up data from REACH
and findings from other PAD registries have revealed higher cardio-
vascular event rates for patients with PAD compared with patients
with coronary artery disease or cerebrovascular disease, and more
effective risk factor control has been shown to be associated with a
lower rate of cardiovascular events.3–5 The most important recent
initiatives to improve management of PAD have been the American
College of Cardiology/American Heart Association (ACC/AHA)
Practice Guidelines for the management of patients with PAD, the
Trans-Atlantic Inter-Society Consensus for the Management of Per-
ipheral Arterial Disease (TASC), and the European Society of Cardi-
ology (ESC)Guidelineson thediagnosis and treatmentofPAD,which
define educational, clinical, and research goals for the near future.6–8
Related to these initiatives, Reinecke et al. now report a contem-
porary data set on 41 882 inpatients treated for PAD in Germany
between 2009 and 2011. The authors illustrate that despite well-
positioned guidelines, outcome of patients with PAD is unchanged
and is particularly poor in those with critical limb ischaemia
irrespective of guidelines that highlight effective approaches to the
care of patients with limb-threatening PAD.9 The interdisciplinary
‘ACC/AHA Guidelines’ published in 2005 defined care algorithms
for acute and chronic critical limb ischaemia. The second inter-
national TransAtlantic Inter-Society Consensus (TASC II) for the
Management of Peripheral Artery Disease published in 2007 empha-
sized early referral to vascular specialists/vascular centres to plan
revascularization.6,7 Revascularization is the recommended primary
treatment option, since critical limb ischaemia is associated with po-
tential limb loss and raised mortality if left untreated. Revasculariza-
tion should be attempted without delay in all patients presenting
with critical limb ischaemia, whenever technically possible and if clin-
ical status is not hopelessly non-ambulatory.10 It goes without saying
that imaging is a cornerstone and no patient should undergo amputa-
tion without angiography.
Interestingly, Reinecke et al. show continuously rising numbers of
revascularizations, butmore so in patientswith intermittent claudica-
tion (Rutherford 1–3). Among the 4298 amputated patients with
critical limb ischaemia (Rutherford 4–6), 37% had not received any
angiography or revascularization, although guidelines provide good
evidence that amputation-free survival can be improved with con-
sequent vascular diagnostics and revascularization regardless of
whether this is endovascular or surgical. In particular, in recent
years, endovascular treatment has become more and more promin-
ent, due to development of new technology and an increase in
endovascular skill. The low morbidity and mortality of these proce-
durescomparedwith surgical revascularization, particularly inpatients
with severe co-morbidity, has expanded the spectrum further. In con-
trast, guidelines from various societies state quite clearly that patients
with intermittent claudication should undergo lifestyle modification
and supervised exercise training first as there is a considerable rate
of recurrences and no proof that the incidence of critical limb
ischaemia will change with early revascularization,11 suggesting that
restricted competence in non-specialized centres or DRG-driven
incentives might have impacted treatment decisions in Germany.
The authors also demonstrate a continuous increase in PAD
burden of 21% from 401 000 cases in 2005 to 484 000 cases in
2009, and an increase of the proportion of critical limb ischaemia
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from 40.6% to 43.5%, creating considerable healthcare costs. Al-
though less than half of the patients suffered from critical limb ischae-
mia, they were responsible for 65% of the E141 million inhospital
costs. A previous report from REACH estimated and compared
vascular-related hospitalization costs in patients enrolled in the
USA with symptomatic coronary artery disease, cerebrovascular
disease, and PAD, and found costs to be higher for patients with
symptomatic PAD, largely because of the high rate of peripheral
revascularization procedures.Overall, approximately half of the hos-
pitalization costs in patients with symptomatic PAD were due to
PAD-specific treatment, whereas the other half were for the treat-
ment of coronary artery or cerebrovascular disease-related athero-
thrombotic events or other cardiovascular reasons.12
Given the impact of PAD, a division in vascular medicine has been
officially recognized by the UE regulatory agency in Europe (Union
Europe´enne des Me´decins Spe´cialistes, UEMS; http://www.uems.
net/EU-Division of Angiology), and a National Institute of Health
(NIH) fellowship programme in clinical vascular medicine has been
advocated in the USA (NHLBI Vascular Medicine Training Program
Working Group; http://www.nhlbi.nih.gov/Meetings/workshops/
vascular-med.htm). This fellowship includes a 2- to 3-year training
periodwith intensive teaching in basic, clinical, pathophysiology, non-
invasive, and invasive diagnostic, prevention, and therapeutic strat-
egies in vascular medicine.13
Peripheral artery disease is a critical cause of cardiovascular mor-
bidity andmortality, and is the primary cause of amputation, and yet is
often not promptly recognized or treated. Although the outcome of
patients with critical limb ischaemia is described to be considerably
improved, with the majority of patients being suitable for revascular-
ization and as major amputation has become an infrequent outcome
event if treated in vascular centres with adequate expertise, this still
seems not to be true outside of specialized centres.14 Last, but not
least, data demonstrate the very high cost of PAD and there still
are insufficient data available that clarifies whether more effective
useof preventive interventions, i.e.moreconsistent useof risk reduc-
tion medications, access to supervised exercise programmes, and
smoking cessation strategies in this population, would reduce
disease progression and costs associated with downstream vascular
resource use. There is no doubt thatmajor efforts need to bemade in
order to heighten awareness of the problem among the medical
community and the general population (Figure 1).
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